You are here: Industry Insights > Daiichi Sankyo

News List

Daiichi Sankyo collaborates with Kyukyu Pharma biospectrumasia
August 10, 2017
Kyukyu Pharmaceutical is currently applying for marketing authorization of fentanyl citrate patches from the Japanese Ministry of Health, Labour and Welfare.
Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation americanpharmaceuticalreview
August 04, 2017
Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. announced that they have agreed to enter into a program to settle, on behalf of all defendants...
Daiichi Sankyo reaches $300-million deal to settle US litigation over hypertension drug firstwordpharma
August 03, 2017
Daiichi Sankyo settle pending product liability litigation in the US for up to $300 million.
Daiichi Sankyo anticoagulant gains EU label boost pharmaphorum
July 24, 2017
Daiichi Sankyo’s Lixiana has gained an EU recommendation for use in patients being treated for an abnormal heart rhythm.
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center announce cancer research collaborati cphi-online
July 13, 2017
Parties to optimize certain novel compounds that target cancer cell transcription and proliferation.
Daiichi Sankyo, Max Planck and Lead Discovery form cancer research partnership pharmaceutical-technology
July 13, 2017
Daiichi Sankyo has signed a new agreement with Max Planck Innovation and Lead Discovery Center to form a new cancer research collaboration.
Big success and even bigger failure for Daiichi Sankyo's experimental therapy pharmafile
July 04, 2017
Daiichi Sankyo has been hit with mixed news this week regarding its experimental therapy mirogabalin. The drug posted trial success in treating patients with post-herpetic neuralgia by hitting its primary endpoint, yet failed to hit its target in a trial
Daiichi Sankyo announces collaborative research on drugs for neglected tropical diseases worldpharmanews
March 31, 2017
Daiichi Sankyo Company, Limited (Daiichi Sankyo), announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi).
Daiichi Sankyo initiates study of U3-1402 in patients with breast cancer pharmaasia
February 16, 2017
U3-1402, the second clinical-stage investigational antibody drug conjugate in the Daiichi Sankyo Cancer Enterprise pipeline, comprises a humanized anti-HER3 antibody attached by a peptide linker to a novel topoisomerase I inhibitor (DXd) payload, utilizin
Kite Pharma joins hands with Daiichi Sankyo for cancer med biospectrumasia
January 11, 2017
Daiichi Sankyo will make an upfront payment to Kite of $50 million and Kite will be eligible to receive future payments totaling up to $200 million for development and commercial milestones

Previous page 1 2 3 4 5 6 7 8 Next page